• 
• 
• 

FDA News and Drug Updates

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

March 08, 2019 – FDA Approvals, News & Updates

Supportive Care

Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting

Meg Barbor, MPH

A Taxing Consequence: Taxane Acute Pain Syndrome

Mark L. Zangardi, PharmD, BCOP

Helping Adolescents and Young Adults Confront Mortality

Meg Barbor, MPH

View All Supportive Care Articles

Lung Cancer

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Atezolizumab plus Chemotherapy New First-Line Regimen for Small-Cell Lung Cancer

A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer

Phoebe Starr

View All Lung Cancer Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

View All Conference Correspondent Articles

Most Popular Articles

February 8, 2019 - FDA Approvals, News & Updates

Web Exclusives - FDA Approvals, News & Updates, In the News

February 1, 2019 - FDA Approvals, News & Updates

Web Exclusives - FDA Approvals, News & Updates, In the News

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

TOP - February 2019, Vol 12, No 1 - Immunotherapy, Renal-Cell Carcinoma

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

Web Exclusives - FDA Approvals, News & Updates, In the News